An observational study in HIV Infection and HIV Infections, sponsored by Universidade Federal de Goias. Completed at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2009-10-29.
Sponsored by Universidade Federal de Goias · Observational
The aim of this study was to delineate the epidemiological profile of HIV seropositive patients on antiretroviral therapy at the Clinical Hospital of the Federal University of Goiás.
Objective: To delineate the epidemiological profile of HIV seropositive patients on antiretroviral therapy at the Clinical Hospital of the Federal University of Goiás.
Methods: The present study is documental and analitical descriptive and it was conducted at the Clinical Hospital of the Federal University of Goiás, trough data collection of 222 records of individuals in drug therapy. Data were collected regarding the personal aspects, aspects related to the infection and information about the most used therapeutic.
6,687 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 222 is close to the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Universidade Federal de Goias is the lead sponsor of 41 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Community sample, with HIV, in drug therapy in the Clinical Hospital of UFG.
Exclusion Criteria:
Seroposite HIV patients that take their treatment at the Clinical Hospital of The Federal University of Goias, and have their records in the hospital.
Data regarding the personal aspects, aspects related to the infection and information about the most used therapeutic.
Time frame: Since the start of the drug therapy ( means of 36 months)
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidade Federal de Goias